Patents by Inventor Daniel P. Gold

Daniel P. Gold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies
    Patent number: 12414934
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: September 16, 2025
    Assignees: Aardvark Therapeutics, Inc., The Spanish National Cancer Research Centre
    Inventors: Daniel P. Gold, Miguel Quintela-Fandino
  • COMBINATION THERAPY OF PI3K INHIBITOR AND PD-1 INHIBITOR
    Publication number: 20250177409
    Abstract: Provided herein are methods of treating proliferative diseases or disorders (e.g., a cancer) in a patient in need thereof using a combination therapy of Compound (I) or a pharmaceutically acceptable salt thereof and a PD-1 inhibitor (e.g., Pembrolizumab).
    Type: Application
    Filed: February 28, 2023
    Publication date: June 5, 2025
    Inventors: Daniel P. GOLD, Richard GHALIE
  • Combination therapy
    Patent number: 12161644
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: December 10, 2024
    Assignee: MEI Pharma, Inc.
    Inventor: Daniel P. Gold
  • TREATMENT OF KRAS MUTANT CANCERS
    Publication number: 20240016781
    Abstract: The disclosure herein provides combination therapies for the treatment of KRAS mutant cancers. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I or a pharmaceutically acceptable salt thereof together with an additional therapeutic agent, e.g., an anticancer agent.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 18, 2024
    Applicant: MEI Pharma, Inc.
    Inventors: Sandra E. Wiley, Daniel P. Gold
  • COMBINATION THERAPIES
    Publication number: 20230233519
    Abstract: Provided herein are compositions, methods, and kits for treating cancer comprising a mitochondrial inhibitor and a Bcl-2 inhibitor.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPY
    Publication number: 20220265673
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a CD20 inhibitor to a patient.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 25, 2022
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPY
    Publication number: 20220193086
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
    Type: Application
    Filed: March 1, 2022
    Publication date: June 23, 2022
    Inventor: Daniel P. GOLD
  • Combination therapy
    Patent number: 11351176
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a CD20 inhibitor to a patient.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 7, 2022
    Assignee: MEI Pharma, Inc.
    Inventor: Daniel P. Gold
  • Combination therapy
    Patent number: 11304953
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 19, 2022
    Assignee: MEI Pharma, Inc.
    Inventor: Daniel P. Gold
  • TREATMENT OF B CELL MALIGNANCIES
    Publication number: 20210299134
    Abstract: Provided herein are methods of treating cancer using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the cancer is follicular lymphoma (FL). In certain embodiments, the PI3K inhibitor is administered on a continuous dosing schedule (CS). In other embodiments, the PI3K inhibitor is administered on an intermittent dosing schedule (IS).
    Type: Application
    Filed: August 13, 2019
    Publication date: September 30, 2021
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPIES
    Publication number: 20210267936
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 2, 2021
    Inventors: Daniel P. GOLD, Miguel QUINTELA-FANDINO
  • TREATMENT OF RELAPSED FOLLICULAR LYMPHOMA
    Publication number: 20210196725
    Abstract: Provided herein are methods treating follicular lymphoma (FL) in subjects having early disease progression after immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the methods comprise treating FL in subjects having disease progression within 24 months of initiating first-line or subsequent immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor.
    Type: Application
    Filed: August 13, 2019
    Publication date: July 1, 2021
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPY
    Publication number: 20210161909
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a cyclin-dependent kinase (CDK) inhibitor to a patient.
    Type: Application
    Filed: August 13, 2019
    Publication date: June 3, 2021
    Inventor: Daniel P. GOLD
  • Combination therapies
    Patent number: 10980774
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: April 20, 2021
    Assignees: MEI PHARMA, INC., THE SPANISH NATIONAL CANCER RESEARCH CENTRE
    Inventors: Daniel P. Gold, Miguel Quintela-Fandino
  • COMBINATION THERAPIES
    Publication number: 20210100775
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a heterocyclic compound and a DNA hypomethylating agent.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 8, 2021
    Inventors: Daniel P. GOLD, Guillermo GARCIA-MANERO
  • COMBINATION THERAPY
    Publication number: 20210000838
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a Bruton tyrosine kinase (BTK) inhibitor to a patient.
    Type: Application
    Filed: March 20, 2019
    Publication date: January 7, 2021
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPY
    Publication number: 20200222415
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a CD20 inhibitor to a patient.
    Type: Application
    Filed: August 14, 2018
    Publication date: July 16, 2020
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPY
    Publication number: 20200197403
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
    Type: Application
    Filed: May 22, 2018
    Publication date: June 25, 2020
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPY
    Publication number: 20190201409
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a second agent selected from a Bruton tyrosine kinase (BTK) inhibitor, a Bcl-2 inhibitor, an EZH2 inhibitor and a combination thereof to a patient.
    Type: Application
    Filed: September 18, 2017
    Publication date: July 4, 2019
    Inventor: Daniel P. GOLD
  • COMBINATION THERAPIES
    Publication number: 20180015067
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 18, 2018
    Inventors: Daniel P. GOLD, Miguel QUINTELA-FANDINO